FcRn-based therapeutics for the treatment of auto-immune disorders
Disclosed is a transgenic knockout mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene. The homozygous FcRn disruption prevents the expression of a functional FcRn protein, resulting in a transgenic knockout mouse in which exogenously administered IgG1 exhibits a substantially shorter half-life, as compared to the half-life of exogenously administered IgG1 in a wild-type mouse. The transgenic knockout mouse with a homozygous FcRn disruption is also unable to absorb maternal IgG in the prenatal or neonatal stage of development. Also disclosed is a transgenic knockout mouse comprising a homozygous FcRn disruption and a human FcRn transgenic. The transgenic addition of human FcRn results in a substantial increase in the half-life of exogenously administered human IgG1. Methods of using the transgenic knockout mouse, and cells derived from them, are also disclosed.
1. A method to identify or characterize an inhibitor of IgG protection by human FcRn (huFcRn) comprising:
a) providing a first and a second transgenic mouse whose genome comprises a homozygous disruption in its endogenous FcRn gene, and whose genome further comprises a DNA sequence encoding a human FcRn operably linked to a regulatory sequence, wherein said homozygous disruption prevents the expression of a functional endogenous FcRn protein, and wherein the mouse expresses a functional human FcRn protein (a muFcRn−/−, +huFcRn transgenic mouse);
b) administering intravenously or intraperitoneally tracer human IgG and tracer human IgA to the first and the second transgenic mouse;
c) administering intravenously or intraperitoneally a candidate inhibitor to the first transgenic mouse; and
d) determining the half-life of the tracer human IgG and the half-life of the tracer human IgA in the first transgenic mouse which has received the candidate inhibitor and in the second transgenic mouse which has not received the candidate inhibitor, with a decrease in the half-life of the tracer human IgG, but not the tracer human IgA, in the first transgenic mouse, as compared to the half life of the tracer human IgG and the tracer human IgA respectively in the second transgenic mouse, being an indication that the candidate inhibitor inhibits FcRn protection of IgG.
2. A method to identify or characterize a candidate agent for FcRn-mediated drug stabilization, comprising:
a) providing a formulation comprising a candidate agent for FcRn-mediated drug stability attached to a trackable composition;
b) administering intravenously or intraperitoneally the formulation to a muFcRn−/−, +huFcRn transgenic mouse, and also to a muFcRn−/− transgenic mouse; and
c) assaying the half-life of the formulation in the bloodstream of the muFcRn−/−, +huFcRn transgenic mouse and in the bloodstream of the muFcRn−/− transgenic mouse, with a substantially longer half-life of the formulation in the bloodstream of the muFcRn−/−, +huFcRn transgenic mouse than in the bloodstream of the muFcRn−/− transgenic mousebeing an indication that the candidate agent promotes FcRn-mediated drug stabilization.
3. The method of claim 2 wherein the candidate agent is derived from an IgG Fc region.
4. The method of claim 2 wherein the candidate agent is derived from an IgG Fc region or fragment thereof, or other molecules which are structurally-similar or similar in sequence identity to the Fc-region of IgG.
5. The method of claim 2 wherein the candidate agent is structurally-similar or similar in sequence identity to the Fc-region of IgG, such that the binding affinity of the candidate agent to the FcRn protein is greater than the binding affinity of the Fc-region of IgG to the FcRn protein.
6. A method for determining the difference in pharmacokinetics of a drug conferred by an FcRn-mediated drug stability candidate agent linked to the drug, comprising:
a) providing a first trackable formulation comprising a drug linked to a FcRn-mediated drug stability candidate agent, and a second trackable formulation comprising the drug without the FcRn-mediated drug stability candidate agent;
b) administering intravenously or intraperitoneally the first formulation to a first muFcRn−/−, +huFcRn transgenic mouse, and the second formulation to a second muFcRn−/−, +huFcRn transgenic mouse;
c) determining the half-lives of the first and the second formulation in the bloodstream of the first and the second muFcRn−/−, +huFcRn transgenic mouse respectively; and
d) comparing the half-lives determined in step c) to one another, thereby determining the difference in half-lives conferred to the drug by the FcRn-mediated drug stability candidate agent.
7. The method of claim 6 wherein the candidate agent is derived from an IgG Fc region.
8. The method of claim 6 wherein the candidate agent is derived from an IgG Fc region or fragment thereof, or other molecules which are structurally-similar or similar in sequence identity to the Fc-region of IgG.
9. The method of claim 6 wherein the candidate agent is structurally-similar or similar in sequence identity to the Fc-region of IgG, such that the binding affinity of the candidate agent to the FcRn protein is greater than the binding affinity of the Fc-region of IgG to the FcRn protein.
10. A method to identify or characterize a candidate agent for FcRn-mediated drug stabilization, comprising:
a) providing a formulation comprising a candidate agent for FcRn-mediated drug stability formulated with a trackable composition;
b) administering intravenously or intraperitoneally the formulation to a muFcRn−/−, +huFcRn transgenic mouse, and also to a muFcRn−/− transgenic mouse; and
c) assaying the half-life of the formulation in the bloodstream of the muFcRn−/−, +huFcRn transgenic mouse and the bloodstream of the muFcRn−/− transgenic mouse, with a substantially longer half-life of the formulation in the bloodstream of the muFcRn−/−, +huFcRn transgenic mouse than in the bloodstream of the muFcRn−/− transgenic mouse being an indication that the candidate agent promotes FcRn-mediated drug stabilization.
11. A method for determining the difference in pharmacokinetics of a drug conferred by an FcRn-mediated drug stability candidate agent linked to the drug, comprising:
a) providing a first trackable formulation comprising a drug linked to a FcRn-mediated drug stability candidate agent, and a second trackable formulation comprising the drug without the FcRn-mediated drug stability candidate agent;
b) administering intravenously or intraperitoneally the first and the second formulation to a muFcRn−/−, +huFcRn transgenic mouse;
c) determining the half-lives of the first and the second formulation in the bloodstream of the muFcRn−/−, +huFcRn transgenic mouse; and
e) comparing the half-lives determined in step c) to one another, thereby determining the difference in half-lives conferred to the drug by the FcRn-mediated drug stability candidate agent.